Affordable Access

deepdyve-link
Publisher Website

Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice

Authors
  • Nojiri, Shunsuke1
  • Tsuchiya, Atsunori1
  • Natsui, Kazuki1
  • Takeuchi, Suguru1
  • Watanabe, Takayuki1
  • Kojima, Yuichi1
  • Watanabe, Yusuke1
  • Kamimura, Hiroteru1
  • Ogawa, Masahiro1
  • Motegi, Satoko1
  • Iwasawa, Takahiro1
  • Sato, Takeki1
  • Kumagai, Masaru1
  • Ishii, Yui1
  • Kitayama, Tomomi2, 3
  • Li, Yu-Tung2
  • Ouchi, Yuya2, 3
  • Shimbo, Takashi2, 2
  • Takamura, Masaaki1
  • Tamai, Katsuto2
  • And 1 more
  • 1 Niigata University,
  • 2 Osaka University,
  • 3 StemRIM Inc., Saito Bio-Incubator 3F 7-7-15, Saito-Asagi, Ibaraki City, Osaka, 567-0085 Japan
Type
Published Article
Journal
Inflammation and Regeneration
Publisher
BioMed Central
Publication Date
Sep 27, 2021
Volume
41
Identifiers
DOI: 10.1186/s41232-021-00177-4
PMID: 34565478
PMCID: PMC8474861
Source
PubMed Central
Keywords
Disciplines
  • Research Article
License
Unknown

Abstract

The liver has a high regenerative ability and can induce spontaneous regression of fibrosis when early liver damage occurs; however, these abilities are lost when chronic liver damage results in decompensated cirrhosis. Cell therapies, such as mesenchymal stem cell (MSC) and macrophage therapies, have attracted attention as potential strategies for mitigating liver fibrosis. Here, we evaluated the therapeutic effects of HMGB1 peptide synthesized from box A of high mobility group box 1 protein. Liver damage and fibrosis were evaluated using a carbon tetrachloride (CCl4)-induced cirrhosis mouse model. The effects of HMGB1 peptide against immune cells were evaluated by single-cell RNA-seq using liver tissues, and those against monocytes/macrophages were further evaluated by in vitro analyses. Administration of HMGB1 peptide did not elicit a rapid response within 36 h, but attenuated liver damage after 1 week and suppressed fibrosis after 2 weeks. Fibrosis regression developed over time, despite continuous liver damage, suggesting that administration of this peptide could induce fibrolysis. In vitro analyses could not confirm a direct effect of HMGB1 peptide against monocyte/macrophages. However, macrophages were the most affected immune cells in the liver, and the number of scar-associated macrophages ( Trem2 + Cd9 + cells) with anti-inflammatory markers increased in the liver following HMGB1 treatment, suggesting that indirect effects of monocytes/macrophages were important for therapeutic efficacy. Overall, we established a new concept for cell-free therapy using HMGB1 peptide for cirrhosis through the induction of anti-inflammatory macrophages. Supplementary Information The online version contains supplementary material available at 10.1186/s41232-021-00177-4.

Report this publication

Statistics

Seen <100 times